Previous 10 |
Curative Biotechnology Announces IMT504 License For Development Of Proprietary Next-Gen COVID-19 Vaccine License from Mid-Atlantic BioTherapeutics for IMT504 Broadens Scope of Initial License Beyond Treatment of Symptomatic Rabies PR Newswire BOCA RATON, Fla. , ...
Company's Clinical Program for CD56 Monoclonal Antibody Drug Conjugate for Treatment of Glioblastoma to Benefit from Exper tise in Neurobiology Boca Raton, FL, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT), announced today the addition...
Boca Raton, FL, July 15, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development stage biomedical company focused on novel therapies for rare diseases, announced today that Marc Drimer, CPA has joined ...
Curative Biotechnology (CUBT): Q1 GAAP EPS of -$0.002.Cash of $0.56MShares -5.45%.Press Release For further details see: Curative Biotechnology reports Q1 results
Boca Raton, FL, May 25, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company targeting novel treatments for rare diseases, filed its Q1 quarterly report for the period...
News, Short Squeeze, Breakout and More Instantly...
Curative Biotechnology Inc Com Company Name:
CUBT Stock Symbol:
OTCMKTS Market:
Curative Biotechnology Inc Com (CUBT) is expected to report for Q1 2022
Appointment of Independent Director Nominee to become effective upon approval by and listing of common stock on a National Exchange Boca Raton, FL, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), ...
Appointment of Independent Director to become effective upon approval by and listing of common stock on a National Exchange Boca Raton, FL, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a develo...